StockStory Favors Cardinal Health, Flags Two Healthcare Names
The publisher pointed to Cardinal Health’s earnings growth while citing slower sales or weaker profitability at Omnicell and Lantheus.
Key takeaways
- StockStory highlighted Cardinal Health’s 14.6% annual EPS growth over five years.
- StockStory cited slow sales growth at Omnicell and Lantheus.
StockStory named Cardinal Health its healthcare stock to watch, while flagging Omnicell and Lantheus as risky. Its assessment came as healthcare stocks had returned 40.7% over six months, beating the S&P 500 by 23.9 percentage points.
The publisher cited Cardinal Health’s $254.2 billion revenue base and said share buybacks helped drive annual earnings-per-share growth of 14.6% over five years. The shares were priced at $233.46, or 18.2 times forward earnings, in the article.
StockStory pointed to Omnicell’s 4.8% annual sales growth over five years and a return on invested capital of 0.1%. For Lantheus, it cited 4% annual revenue growth over two years and projected a 1.2% sales decline over the next 12 months.
This article was produced with the help of AI technology. Source: Yahoo Finance
